Nicolai J Wewer Albrechtsen Selected Research

Glucagon (Glukagon)

1/2022	On measurements of glucagon secretion in healthy, obese, and Roux-en-Y gastric bypass operated individuals using sandwich ELISA.
1/2022	The Liver-α-Cell Axis in Health and in Disease.
10/2021	Glucagon Clearance is Preserved in Type 2 Diabetes.
10/2021	Glucagon Clearance is Preserved in Type 2 Diabetes.
9/2021	Neprilysin Inhibition Increases Glucagon Levels in Humans and Mice With Potential Effects on Amino Acid Metabolism.
5/2021	Metabolic effects of 1-week binge drinking and fast food intake during Roskilde Festival in young healthy male adults.
2/2021	Plasma levels of glucagon but not GLP-1 are elevated in response to inflammation in humans.
1/2021	The liver-alpha cell axis associates with liver fat and insulin resistance: a validation study in women with non-steatotic liver fat levels.
1/2021	No effects of dapagliflozin, metformin or exercise on plasma glucagon concentrations in individuals with prediabetes: A post hoc analysis from the randomized controlled PRE-D trial.
1/2021	Evidence for Glucagon Secretion and Function Within the Human Gut.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Nicolai J Wewer Albrechtsen Research Topics

Disease

23	Type 2 Diabetes Mellitus (MODY) 10/2022 - 09/2014
19	Obesity 01/2022 - 09/2014
10	Weight Loss (Weight Reduction) 01/2021 - 01/2016
9	Insulin Resistance 05/2021 - 12/2016
8	Hypoglycemia (Reactive Hypoglycemia) 01/2021 - 01/2016
7	Body Weight (Weight, Body) 10/2021 - 01/2016
6	Non-alcoholic Fatty Liver Disease 01/2022 - 11/2016
6	Metabolic Diseases (Metabolic Disease) 01/2022 - 12/2016
5	Hyperplasia 01/2018 - 01/2016
4	Liver Diseases (Liver Disease) 01/2022 - 01/2018
4	Dyslipidemias (Dyslipidemia) 01/2022 - 01/2019
4	Inflammation (Inflammations) 10/2021 - 12/2016
4	Hyperglycemia 01/2020 - 11/2017
4	Neoplasms (Cancer) 07/2019 - 11/2016
3	Glucagonoma 07/2019 - 01/2016
2	Heart Failure 10/2022 - 09/2021
2	Prediabetic State (Prediabetes) 01/2021 - 01/2019
2	Overweight 01/2021 - 01/2019
2	Fibrosis (Cirrhosis) 05/2020 - 01/2019
2	Fatty Liver 01/2020 - 10/2019
2	Glucose Intolerance 01/2020 - 10/2019
2	Chronic Kidney Failure (Chronic Renal Failure) 01/2020 - 09/2014
2	Hyperinsulinism (Hyperinsulinemia) 01/2020 - 10/2019
1	Liver Cirrhosis (Hepatic Cirrhosis) 01/2022
1	Neuroendocrine Tumors (Neuroendocrine Tumor) 01/2022
1	Endocarditis 02/2021
1	Bacterial Infections (Bacterial Infection) 02/2021
1	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/2021
1	Binge-Eating Disorder (Binge Eating Disorder) 01/2021
1	Thinness 11/2020
1	Malnutrition (Nutritional Deficiencies) 10/2020
1	Bone Resorption 09/2020
1	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 01/2020
1	Nausea 01/2020
1	Hyperphagia (Overeating) 10/2019
1	Prostatic Neoplasms (Prostate Cancer) 01/2019

Drug/Important Bio-Agent (IBA)

28	Glucagon (Glukagon)FDA Link 01/2022 - 09/2014
25	Glucose (Dextrose)FDA LinkGeneric 10/2022 - 01/2016
11	Glucagon-Like Peptide 1 (GLP 1)IBA 10/2022 - 01/2016
10	Insulin (Novolin)FDA Link 11/2020 - 01/2016
9	Amino Acids FDA Link 01/2022 - 01/2016
8	Glucagon Receptors (Glucagon Receptor)IBA 01/2022 - 01/2016
8	Proteins (Proteins, Gene)FDA Link 01/2022 - 12/2016
6	Hormones (Hormone)IBA 01/2021 - 05/2017
5	IncretinsIBA 01/2020 - 12/2016
4	Alanine (L-Alanine)FDA Link 01/2021 - 01/2018
3	ProteomeIBA 01/2022 - 12/2016
3	Blood Glucose (Blood Sugar)IBA 02/2021 - 01/2018
3	GlicentinIBA 01/2021 - 01/2020
3	Glucagon-Like Peptide-1 Receptor AgonistsIBA 01/2020 - 12/2016
3	OxyntomodulinIBA 01/2020 - 05/2016
3	Dipeptidyl-Peptidase IV InhibitorsIBA 01/2020 - 01/2017
2	sacubitril and valsartan sodium hydrate drug combinationIBA 10/2022 - 09/2021
2	Neprilysin (Neutral Endopeptidase)IBA 10/2022 - 09/2021
2	Biomarkers (Surrogate Marker)IBA 10/2021 - 01/2019
2	C-PeptideIBA 05/2021 - 05/2017
2	Interleukin-6 (Interleukin 6)IBA 02/2021 - 09/2020
2	Glucagon-Like Peptide-1 ReceptorIBA 01/2020 - 01/2018
2	Exenatide (Byetta)FDA Link 01/2020 - 01/2016
2	Blood Proteins (Serum Proteins)IBA 01/2019 - 12/2016
2	EnzymesIBA 01/2018 - 12/2016
1	Angiotensin Receptor AntagonistsIBA 10/2022
1	Pancreatic HormonesIBA 10/2022
1	G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA 01/2022
1	Fatty Acids (Saturated Fatty Acids)IBA 01/2022
1	Peptides (Polypeptides)IBA 01/2022
1	Peptide Hydrolases (Proteases)FDA Link 09/2021
1	fibroblast growth factor 21IBA 05/2021
1	C-Reactive ProteinIBA 02/2021
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 02/2021
1	Indicators and Reagents (Reagents)IBA 01/2021
1	FollistatinIBA 01/2021
1	Metformin (Glucophage)FDA LinkGeneric 01/2021
1	dapagliflozinIBA 01/2021
1	SodiumIBA 01/2021
1	activin AIBA 01/2021
1	Interleukin 1 Receptor Antagonist Protein (Anakinra)FDA Link 11/2020
1	ProcollagenIBA 09/2020
1	Collagen Type I (Type I Collagen)IBA 09/2020
1	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 05/2020
1	Sitagliptin Phosphate (Januvia)FDA Link 01/2020
1	Gastrointestinal Hormones (Hormones, Gastrointestinal)IBA 01/2020
1	Interleukin-6 Receptors (Interleukin 6 Receptor)IBA 01/2020
1	PlacebosIBA 01/2020
1	tocilizumab (atlizumab)FDA Link 01/2020
1	LipidsIBA 10/2019
1	GelatinIBA 01/2019
1	2-methylcyclopentadienyl manganese tricarbonyl (MMT)IBA 01/2019
1	Glycoproteins (Glycoprotein)IBA 01/2019
1	Conditioned Culture MediaIBA 01/2019

Therapy/Procedure

12	Gastric Bypass (Roux-en-Y Gastric Bypass) 01/2021 - 09/2014
5	Therapeutics 01/2021 - 12/2016
5	Bariatric Surgery 11/2020 - 12/2018
2	Gastrectomy 10/2020 - 01/2020
1	Endovascular Aneurysm Repair 02/2021
1	Operative Surgical Procedures 10/2020
1	Biliopancreatic Diversion 10/2020
1	Liver Transplantation 05/2020
1	Renal Dialysis (Hemodialysis) 01/2020
1	Subcutaneous Injections 01/2020